Biocept
Biocept to Refocus CNSide Assay Plans After FDA Feedback Suggests Targeting Narrower Indications
Premium
The company failed in its first bid for breakthrough device designation but has now split out new specific indications for which it is building more persuasive utility data.
Biocept Q3 Revenues Jump 165 Percent on COVID-19 Testing Impact
The company posted $17.5 million in revenues, citing increased testing driven by the emerging Delta variant, as well its deal to provide tests for California community colleges.
Biocept Q2 Revenues Continue COVID-19-Driven Spike
The company saw a slowdown in its virus testing from Q1 but still dwarfed its Q2 2020 results, as COVID-19 assays continued to outweigh its core cancer business.
Biocept HER2 Assay Gains Coverage Under Medicare Local Coverage Determination for CTC Tests
Under the LCD, CTC assays, such as Biocept's, will now be covered to guide targeted treatment decisions for patients with breast and other cancers under certain circumstances.
Mar 31, 2021
May 13, 2020
Biocept Q1 Revenues Up 41 Percent
Apr 27, 2020